Incidence and Predictors of Complications With Sacral Neuromodulation

Wesley White, Joe D. Mobley, Regula Doggweiler, Cindy Dobmeyer-Dittrich, Frederick A. Klein

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objectives: To determine the incidence and predictors of complications with sacral nerve stimulation (SNS). Methods: A prospective, longitudinal analysis of all patients treated with SNS was performed to define the incidence of complications and identify the predictors of these adverse events (AEs). All patients underwent staged SNS placement with the InterStim device for treatment of refractory voiding dysfunction. The patients were followed up for evidence of AEs and device efficacy. The patient and device variables were examined statistically for evidence of predictive value. Results: From September 2001 to March 2008, 221 patients with a mean age of 48.8 years underwent SNS lead placement for the treatment of intractable urinary urgency/frequency (n = 121), urge incontinence (n = 63), or urinary retention (n = 37). Of this group, 202 patients (91.4%) experienced a >50% improvement in symptoms and underwent implantable pulse generator placement. At a mean follow-up of 36.9 months, 67 patients (30.3%) had experienced AEs (pain in 6, elective removal in 10, lack of efficacy in 11, trauma in 18, infection in 7, hematoma in 3, and lead migration in 12) requiring 44 lead revisions and 47 implantable pulse generator revisions. The significant predictors of AEs included a history of trauma (P < .001), a change in body mass index class (P < .001), enrollment in a pain clinic (P = .008), the duration of follow-up (P = .002), and a history of AEs (P < .001). Conclusions: The results of our study have shown that SNS is an effective treatment for patients with intractable voiding dysfunction. Complications are not uncommon but can be minimized with better patient selection.

Original languageEnglish (US)
Pages (from-to)731-735
Number of pages5
JournalUrology
Volume73
Issue number4
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Incidence
Equipment and Supplies
Urge Urinary Incontinence
Pain Clinics
Urinary Retention
Wounds and Injuries
Hematoma
Patient Selection
Body Mass Index
Therapeutics
Pain
Infection

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

White, W., Mobley, J. D., Doggweiler, R., Dobmeyer-Dittrich, C., & Klein, F. A. (2009). Incidence and Predictors of Complications With Sacral Neuromodulation. Urology, 73(4), 731-735. https://doi.org/10.1016/j.urology.2008.11.047

Incidence and Predictors of Complications With Sacral Neuromodulation. / White, Wesley; Mobley, Joe D.; Doggweiler, Regula; Dobmeyer-Dittrich, Cindy; Klein, Frederick A.

In: Urology, Vol. 73, No. 4, 01.04.2009, p. 731-735.

Research output: Contribution to journalArticle

White, W, Mobley, JD, Doggweiler, R, Dobmeyer-Dittrich, C & Klein, FA 2009, 'Incidence and Predictors of Complications With Sacral Neuromodulation', Urology, vol. 73, no. 4, pp. 731-735. https://doi.org/10.1016/j.urology.2008.11.047
White W, Mobley JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Incidence and Predictors of Complications With Sacral Neuromodulation. Urology. 2009 Apr 1;73(4):731-735. https://doi.org/10.1016/j.urology.2008.11.047
White, Wesley ; Mobley, Joe D. ; Doggweiler, Regula ; Dobmeyer-Dittrich, Cindy ; Klein, Frederick A. / Incidence and Predictors of Complications With Sacral Neuromodulation. In: Urology. 2009 ; Vol. 73, No. 4. pp. 731-735.
@article{f0aeecd43f31424d981daacc6dce601f,
title = "Incidence and Predictors of Complications With Sacral Neuromodulation",
abstract = "Objectives: To determine the incidence and predictors of complications with sacral nerve stimulation (SNS). Methods: A prospective, longitudinal analysis of all patients treated with SNS was performed to define the incidence of complications and identify the predictors of these adverse events (AEs). All patients underwent staged SNS placement with the InterStim device for treatment of refractory voiding dysfunction. The patients were followed up for evidence of AEs and device efficacy. The patient and device variables were examined statistically for evidence of predictive value. Results: From September 2001 to March 2008, 221 patients with a mean age of 48.8 years underwent SNS lead placement for the treatment of intractable urinary urgency/frequency (n = 121), urge incontinence (n = 63), or urinary retention (n = 37). Of this group, 202 patients (91.4{\%}) experienced a >50{\%} improvement in symptoms and underwent implantable pulse generator placement. At a mean follow-up of 36.9 months, 67 patients (30.3{\%}) had experienced AEs (pain in 6, elective removal in 10, lack of efficacy in 11, trauma in 18, infection in 7, hematoma in 3, and lead migration in 12) requiring 44 lead revisions and 47 implantable pulse generator revisions. The significant predictors of AEs included a history of trauma (P < .001), a change in body mass index class (P < .001), enrollment in a pain clinic (P = .008), the duration of follow-up (P = .002), and a history of AEs (P < .001). Conclusions: The results of our study have shown that SNS is an effective treatment for patients with intractable voiding dysfunction. Complications are not uncommon but can be minimized with better patient selection.",
author = "Wesley White and Mobley, {Joe D.} and Regula Doggweiler and Cindy Dobmeyer-Dittrich and Klein, {Frederick A.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1016/j.urology.2008.11.047",
language = "English (US)",
volume = "73",
pages = "731--735",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Incidence and Predictors of Complications With Sacral Neuromodulation

AU - White, Wesley

AU - Mobley, Joe D.

AU - Doggweiler, Regula

AU - Dobmeyer-Dittrich, Cindy

AU - Klein, Frederick A.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Objectives: To determine the incidence and predictors of complications with sacral nerve stimulation (SNS). Methods: A prospective, longitudinal analysis of all patients treated with SNS was performed to define the incidence of complications and identify the predictors of these adverse events (AEs). All patients underwent staged SNS placement with the InterStim device for treatment of refractory voiding dysfunction. The patients were followed up for evidence of AEs and device efficacy. The patient and device variables were examined statistically for evidence of predictive value. Results: From September 2001 to March 2008, 221 patients with a mean age of 48.8 years underwent SNS lead placement for the treatment of intractable urinary urgency/frequency (n = 121), urge incontinence (n = 63), or urinary retention (n = 37). Of this group, 202 patients (91.4%) experienced a >50% improvement in symptoms and underwent implantable pulse generator placement. At a mean follow-up of 36.9 months, 67 patients (30.3%) had experienced AEs (pain in 6, elective removal in 10, lack of efficacy in 11, trauma in 18, infection in 7, hematoma in 3, and lead migration in 12) requiring 44 lead revisions and 47 implantable pulse generator revisions. The significant predictors of AEs included a history of trauma (P < .001), a change in body mass index class (P < .001), enrollment in a pain clinic (P = .008), the duration of follow-up (P = .002), and a history of AEs (P < .001). Conclusions: The results of our study have shown that SNS is an effective treatment for patients with intractable voiding dysfunction. Complications are not uncommon but can be minimized with better patient selection.

AB - Objectives: To determine the incidence and predictors of complications with sacral nerve stimulation (SNS). Methods: A prospective, longitudinal analysis of all patients treated with SNS was performed to define the incidence of complications and identify the predictors of these adverse events (AEs). All patients underwent staged SNS placement with the InterStim device for treatment of refractory voiding dysfunction. The patients were followed up for evidence of AEs and device efficacy. The patient and device variables were examined statistically for evidence of predictive value. Results: From September 2001 to March 2008, 221 patients with a mean age of 48.8 years underwent SNS lead placement for the treatment of intractable urinary urgency/frequency (n = 121), urge incontinence (n = 63), or urinary retention (n = 37). Of this group, 202 patients (91.4%) experienced a >50% improvement in symptoms and underwent implantable pulse generator placement. At a mean follow-up of 36.9 months, 67 patients (30.3%) had experienced AEs (pain in 6, elective removal in 10, lack of efficacy in 11, trauma in 18, infection in 7, hematoma in 3, and lead migration in 12) requiring 44 lead revisions and 47 implantable pulse generator revisions. The significant predictors of AEs included a history of trauma (P < .001), a change in body mass index class (P < .001), enrollment in a pain clinic (P = .008), the duration of follow-up (P = .002), and a history of AEs (P < .001). Conclusions: The results of our study have shown that SNS is an effective treatment for patients with intractable voiding dysfunction. Complications are not uncommon but can be minimized with better patient selection.

UR - http://www.scopus.com/inward/record.url?scp=63149109060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63149109060&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2008.11.047

DO - 10.1016/j.urology.2008.11.047

M3 - Article

VL - 73

SP - 731

EP - 735

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -